Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00363038|
Recruitment Status : Completed
First Posted : August 15, 2006
Results First Posted : December 4, 2012
Last Update Posted : June 4, 2014
|Condition or disease||Intervention/treatment|
|Ecchymosis||Drug: Petrolatum United States Pharmacopeia (USP) Drug: Vitamin K and retinol ointment Drug: Arnica ointment Drug: Vitamin K ointment|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising|
|Study Start Date :||July 2006|
|Primary Completion Date :||August 2006|
|Study Completion Date :||August 2006|
Bruises at three time points: immediate after bruise creating, and at 1 and 2 weeks.
Drug: Petrolatum United States Pharmacopeia (USP)
Topical formation applied to bruise twice daily for 2 weeks.Drug: Vitamin K and retinol ointment
Topical formation applied to bruise twice daily for 2 weeks.Drug: Arnica ointment
Topical formation applied to bruise twice daily for 2 weeks.Drug: Vitamin K ointment
Topical formation applied to bruise twice daily for 2 weeks.
- Average Bruise Change [ Time Frame: Baseline and 2 weeks ]Mean change in bruising level detected by dermatologist rater on Visual Analogue Scale at 2 weeks compared with baseline for each of the four agents (Petrolatum USP, Vitamin K and retinol ointment, Vitamin K ointment, Arnica ointment). When responding to a VAS item, respondents specify the bruise severity by indicating a position along a continuous line between two end-points (0 and 10, 10 being the most bruised).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00363038
|United States, Illinois|
|Northwestern University Feinberg School of Medicine, Department of Dermatology|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Murad Alam, MD||Northwestern University|